EFFECTIVENESS AND RENAL SAFETY OF TAF/FTC/EVG/cobi IN REAL CLINICAL PRACTICE

A. Alcalá Soto1, L. Jiménez Pichardo1, P. Gómez Germá1, A. Varas Pérez1, C. Puivecino Moreno1, I. Marin Ariza1, MT Gómez de Travecedo-Calvo1

Hospital SAS Jerez de la Frontera, Pharmacy Service, Cádiz, Spain

Background

Tenofovir alafenamide (TAF) is a new molecule that is replacing TDF—original formulation of tenofovir (TDF)—because of its improved efficacy and safety profile in HIV patients.

Purpose

To analyze efficacy and renal safety of TAF/FTC/EVG/cobi antiretroviral therapy (ART) in real clinical practice.

Material and methods

• Retrospective study including all patients who started treatment with TAF/FTC/EVG/cobi.
• Patients were divided into 2 subgroups: naive and pretreated with other ARTs patients.
• Effectiveness: plasma-HIV RNA (viral load) and CD4-T-lymphocyte (CD4) cell count were measured at baseline and after 6 month treatment. Viral load <20 copies/ml was considered as effective.
• Safety: glomerular filtration rate (GFR) and urinary protein to creatinine ratio. Renal involvement was considered if GFR <60 ml/min.

Results

98 patients were analyzed, mean age was 46 years

<table>
<thead>
<tr>
<th>NAIVE SUBGROUP</th>
<th>PRETREATED SUBGROUP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients number</td>
<td>8 patients (8%)</td>
</tr>
<tr>
<td>Plasma-HIV RNA</td>
<td>6/8 patients &lt;20 copies/ml after therapy</td>
</tr>
<tr>
<td>Mean CD4 ratio</td>
<td>181 to 221 cel/µL</td>
</tr>
<tr>
<td>Mean GFR</td>
<td>115 ml/min to 107.3 ml/min (↓7%)</td>
</tr>
</tbody>
</table>

Conclusion

TAF/FTC/EVG/cobi therapy was described to be effective and safe in both naive and pretreated patients in clinical practice.